Alto Neuroscience Inc
For the period ended Dec 31, 2023. Filed Mar 21, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 21, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Signatures
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Annual Report to be signed on its behalf by the undersigned, thereunto duly authorized.
| ALTO NEUROSCIENCE, INC. | |||
| Date: | March 21, 2024 | By: | /s/ Amit Etkin |
|---|---|---|---|
| Amit Etkin, M.D., Ph.D.President and Chief Executive Officer | |||
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this report has been signed below by the following persons in the capacities and on the dates indicated:
| Signature | Title | Date |
|---|---|---|
| /s/ Amit Etkin | President, Chief Executive Officer, and | March 21, 2024 |
| Amit Etkin, M.D., Ph.D. | Chair of the Board of Directors | |
| (Principal Executive Officer) | ||
| /s/ Nicholas Smith | Chief Financial Officer | March 21, 2024 |
| Nicholas Smith | (Principal Financial Officer and Principal Accounting Officer) | |
| /s/ Po Yu (Jeff) Chen, Ph.D. | Director | March 21, 2024 |
| Po Yu (Jeff) Chen, Ph.D. | ||
| /s/ Christopher Nixon Cox | Director | March 21, 2024 |
| Christopher Nixon Cox | ||
| /s/ Andrew Dreyfus | Director | March 21, 2024 |
| Andrew Dreyfus | ||
| /s/ Husseini Manji, M.D. | Director | March 21, 2024 |
| Husseini Manji, M.D. | ||
| /s/ Maha Radhakrishnan, M.D. | Director | March 21, 2024 |
| Maha Radhakrishnan, M.D. | ||
| /s/ Gwill York | Director | March 21, 2024 |
| Gwill York | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.